The Macquarie University Hospital is a private teaching hospital owned by Macquarie University. The hospital is located within Macquarie University and is the first private hospital to be located on a university campus in Australia.

There are 144 beds in Macquarie University Hospital.

During the past decade, Macquarie University Hospital conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 15 clinical trials were completed, i.e. on average, 31.9% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 13 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Macquarie University Hospital" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Bayer" with 4 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored, "HighLife SAS" with 2 trials sponsored and "Abbott Medical Devices" with 2 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Macquarie University Hospital" #1 collaborator was "Breast International Group" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Macquarie University Hospital" are "Breast Cancer" (6 trials), "Prostate Cancer" (3 trials), "Renal Cell Carcinoma" (3 trials), "Advanced Solid Tumors" (2 trials) and "Carcinoma, Transitional Cell" (2 trials). Many other conditions were trialed in "Macquarie University Hospital" in a lesser frequency.

Most popular intervention types in "Macquarie University Hospital" are "Drug" (40 trials), "Device" (6 trials), "Other" (4 trials), "Biological" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Atezolizumab" (7 trials), "Cabozantinib" (3 trials), "Fulvestrant" (3 trials) and "Ipatasertib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Macquarie University Hospital" are 37 trials for "All" genders, 9 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Macquarie University Hospital". 1 are not yet recruiting, 19 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Macquarie University Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Macquarie University Hospital, 6 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".